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Introduction
The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic 
glutamate receptor that has important roles in synaptic transmis-
sion and synaptic plasticity, and has been implicated in a range of 
neurological disorders (reviewed in (Paoletti et al., 2013)). It 
is remarkable for its high Ca2+ permeability (MacDermott et al., 
1986), requirement for glycine as a co-agonist (Johnson & Ascher, 
1987) and block by Mg2+, which underlies the NMDAR’s volt-
age-dependence and hence role as a “molecular coincidence 
detector” (Mayer et al., 1984; Nowak et al., 1984). NMDARs 
are heterotetramers comprised of two GluN1 subunits and two 
others, of which GluN2A and GluN2B are the commonest in the 
mammalian forebrain (Monyer et al., 1994; Watanabe et al., 
1992). GluN2A is predominantly expressed post-natally in rodents 
(Monyer et al., 1994; Watanabe et al., 1992) and humans (Law 
et al., 2003), where it is thought to frequently associate with 
GluN2B subunits to form triheteromeric GluN2A/2B NMDARs 
(reviewed in Wyllie et al., 2013).
Recently, advances in sequencing technology have allowed a 
large number of de novo and inherited GluN2A mutations to be 
identified in individuals with a range of neurodevelopmental dis-
orders, including epilepsy, intellectual disability, autism and 
schizophrenia (Burnashev & Szepetowski, 2015). Some of these 
mutations are gene disrupting, likely resulting in haploinsuf-
ficiency, and so far all associated with epilepsy. Other mutations 
are missense, potentially resulting in a NMDAR with altered 
function. Identifying the functional consequences, if any, of 
such mutations may allow insight into key mechanistic pathways 
underlying the neurodevelopmental disorders with which they 
are associated. However, it is likely that some mutations are not 
relevant to the disorders of their carriers, leading either to 
receptors with no altered function or alterations that are easily 
compensated for. Distinguishing between mutations that may 
be pathogenic, and those that are coincidental, aids mechanistic 
understanding, therapeutics, and genetic counselling.
GluN2AR586K was first identified as being maternally inherited 
in a person with intellectual disability and either epilepsy or 
an abnormal EEG (Endele et al., 2010). The phenotype of the 
proband’s mother was not reported. GluN2AR586K has undergone 
no previous functional assessment. However, in silico predic-
tion tools found it to be “possibly damaging” and “non-neutral” 
(Endele et al., 2010), albeit it is a conservative, within-class 
amino acid substitution, with both arginine and lysine being pos-
itively charged. The substitution alters a residue in the cytosolic 
loop linking the subunit’s M1 and M2 pore domains (Monyer 
et al., 1992), which has so far not been linked to any particular 
function. However, the loop’s proximity to the pore suggests 
that any functional consequences could include an impact on ion 
permeation and/or block of the pore by Mg2+ ions. In the present 
study, we performed the first known functional analysis of the 
GluN2AR586K variant. We made electrophysiological record-
ings from NMDARs containing mutant subunits expressed in 
Xenopus laevis oocytes and primary cultured neurons, allowing 
us to assess the variant’s impact on block by Mg2+ ions, single 
channel conductance, mean open time and NMDAR current 
density. We found that the GluN2AR586K variant did not affect any 
of the parameters assessed.
Materials and Methods
Constructs
The cDNA for wild type human NMDA subunit GluN1-1a (here-
after GluN1) (GenBank accession code NP_015566), GluN2A 
(GenBank accession code NP_000824; (Hedegaard et al., 2012)) 
and GluN2AR586K were gifts from Dr Kasper Hansen and Dr Honjie 
Yuan (University of Emory, Atlanta, GA, USA). The GluN2AR586K 
variant was confirmed by Sanger sequencing. All cDNAs were 
expressed via a pCI-neo vector.
      Amendments from Version 1
We thank the referees for their detailed and thoughtful appraisal 
of our manuscript. Where possible, we have improved the 
manuscript in line with their suggestions. The changes we have 
made are:
Abstract: We have added the human gene name. We had already 
stated that mutations are found in those with neurodevelopmental 
disorders.
Introduction: We have added further information on GRIN2A 
genetic variation in neurodevelopmental disorders, however, we 
have kept this brief as our aim is not to review the area. We have 
added further content in line with the referees’ suggestions.
Results: The concentration of extracellular Mg2+ used is the 
most relevant one as it is approximately physiological. Although 
repeating the experiment with different concentrations of Mg2+ 
could strengthen our conclusion of no effect on the potency of  
Mg2+ block, it seems unlikely, given the location of the mutation, 
that voltage-dependent block by extracellular Mg2+ ions would be 
affected.
We inadvertently included text in the Methods referring to Mg2+ 
block at different holding potentials; these experiments were not 
carried out in the present study and we apologize for our error.  
We have updated the methods to reflect the fact that Mg2+ was 
only studied at one holding potential.
Desensitisation: pyramidal cortical neurons are relatively large 
cells with extensive dendritic arborisations and as such are 
unfortunately not amenable to studies of desensitisation due to 
the inability to have rapid solution exchange.
Closed time analysis: we did not analyse or report closed times 
or open probability due to uncertainty in knowing how many 
channels were present in patches. Open times remain valid to 
analyse because sections with multiple channels open at once 
can be discarded.
Discussion: We have added further content in line with the 
referees’ suggestions, emphasising that alternative functional 
impacts may exist and the limited extent of our study.
See referee reports
REVISED
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Two-electrode voltage-clamp recordings
cRNA for wild type and mutant subunits was synthesized from lin-
earized plasmid DNA as runoff transcripts using the T7 polymerase 
mMessage machine RNA synthesis kit (Life Technologies Ltd, 
Paisley, UK). Each oocyte was injected with 3.7–9 ng of cRNA, 
comprising a 1:1 molar ratio of GluN1 and GluN2A diluted in 
RNAse free water.
Stage V-VI X. laevis oocytes were obtained from the UK Xenopus 
centre (Portsmouth, UK) and from Diaclean (CastropRauxel, 
Germany), collagenased (200 units/ml for 60 minutes), then manu-
ally defolliculated prior to injection. After injection, oocytes were 
placed in separate wells of 24-well plates containing a modified 
Barth’s solution with composition (in mM): 88 NaCl, 1 KCl, 2.4 
NaHCO3, 0.82 MgCl2, 0.44 CaCl2, 0.33 Ca(NO3)2, 15 Tris-HCl; 
adjusted to pH 7.35 with NaOH. This solution was supplemented 
with 50 IU/ml penicillin, 50 mg/ml streptomycin and 50mg/ml 
tetracycline. Oocytes were placed in an incubator (16–21°C) for 
24–48 hours to encourage receptor expression and subsequently 
stored at 4°C. Recordings were made 48–96 hours post injection.
Two-electrode voltage-clamp recordings were made at room 
temperature (18–21°C) from oocytes that were placed in a solution 
that contained (in mM): 115 NaCl, 2.5 KCl, 10 HEPES, 1.8 BaCl2, 
0.01 EDTA; pH 7.35 with NaOH. Recordings were made using a 
GeneClamp 500B amplifier (Molecular Devices, Union City, CA, 
USA). Current and voltage electrodes were made from thin-walled 
borosilicate glass (GC150TF-7.5, Harvard Apparatus, Kent, UK) 
using a PP-830 electrode puller (Narashige Instruments, Tokyo, 
Japan). Filling with 3 M KCl gave resistances of between 0.2 and 
1.5 MΩ. Application of solutions was determined manually. 
Data were filtered at 10 Hz and digitized at 100 Hz via a 1401 
plus analogue-digital interface (Cambridge Electronic Design, 
Cambridge, UK) using WinEDR software (version 3.2.7; 
Strathclyde Electrophysiology Software, Strathclyde University, 
Glasgow, UK). Oocytes were voltage-clamped at –60 mV. 
Recordings were rejected if the holding current (in nA) was 
greater than three times the holding potential (in mV), or if 
the holding current drifted by more than 10% of the agonist 
response across the course of the experiment.
Single-channel voltage-clamp recordings
Single-channel voltage-clamp recordings were made at room 
temperature from outside-out patches pulled from oocytes that 
were placed in a solution that contained (in mM): 125 NaCl, 
3 KCl, 1.25 NaH2PO4, 20 HEPES, 0.85 CaCl2, 0.01 EDTA; pH 7.35 
with NaOH. Steady state recordings were made in the presence of 
30 μM glutamate and 30 μM glycine. Recording durations 
varied from 30 seconds to 5 minutes. Prior to recording, vitel-
line membranes were manually removed from oocytes following 
placement in a hypertonic solution that contained (in mM): 
200 sodium methyl sulphate, 20 KCl, 10 HEPES, 1 MgCl2; pH 7.4 
with NaOH. Recordings were made using an AxoPatch 1D ampli-
fier (Molecular Devices). Electrodes were made using thick walled 
borosilicate glass (GC150F-7.5; Harvard Apparatus) using a P-87 
electrode puller (Sutter Instrument, Novato, CA, USA) and their 
tips fire polished to give resistances of 7 to 12 MΩ when filled with 
internal solution containing (in mM): 2.5 NaCl, 141 K-gluconate, 
10 HEPES, 11 EGTA; pH 7.4 with KOH. Electrode tips were coated 
in silicone elastomer (“sylgard 184”; Dow Corning, Wiesbaden, 
Germany) to reduce capacitance. Application of solutions was 
controlled manually. Data were prefiltered at 2 kHz (–3 dB; 8th 
order Bessel filter) and digitized at 20 kHz via a Micro 1401 
analogue-digital interface (Cambridge Electronic Design) using 
WinEDR software (v 3.2.7). Patches were voltage-clamped 
at –60 or –100 mV.
WinEDR v3.3.7 was used to idealise the traces (using a transition 
threshold of 50% of the unitary conductance level and a 100 μs 
open and shut resolution), to fit Gaussian curves to amplitude his-
tograms and to fit exponential curves to dwell time durations (all 
curves fitted using iterative maximum likelihoods). Any openings 
where more than one channel was open simultaneously were dis-
carded. Conductance was calculated by dividing the current ampli-
tude by the holding potential.
Preparation and transfection of neurons
Animal breeding, maintenance and procedures were performed 
in accordance with the UK Animal Scientific Procedures Act 
(1986). Culturing was a modified version of (Furshpan & Potter, 
1989). Brains from E17.5 CD1 mice (sex not determined, on aver-
age 15 mice per culture) were microdissected in medium contain-
ing (in mM): 8.8 Na2SO4, 27 K2SO4, 5.3 MgCl2, 0.23 CaCl2, 0.9 
HEPES, 0.001% Phenol Red, 18 D-glucose, 0.0005 kynurenic 
acid; adjusted to pH 7.35 with NaOH. Cortices were incubated at 
37°C for 40 minutes in papain enzyme (36,000 USP units/ml; 
Worthington Biochemical Corporation, Lakewood, NJ, USA) 
then washed and triturated in NeuroBasal A medium (supple-
mented with 1% rat serum (Harlan Laboratories, Bicester, UK), 
1 × B-27 supplement, 1% antibacterial/antimycotic and 1 mM 
glutamine). The cell suspension was diluted in opti-MEM (sup-
plemented with 20 mM glucose and 1% antibacterial/antimy-
cotic) to give an end concentration of 1 hemisphere per 7 ml, and 
0.5 ml/coverslip plated onto 13 mm diameter coverslips pre-
coated with poly-D-lysine (1.33% w/v in H20) and laminin 
(0.5% w/v) (Roche, Basel, Switzerland) in 24-well plates. Plates 
were kept at 37°C in a humidified 5% CO2 incubator for 2.5 hours 
before replacement of the cell suspension with supplemented 
NeuroBasal A. On day in vitro (DIV) 4, 1 ml/well of supplemented 
NeuroBasal A containing 9.6 mM cytosine β-D-arabinofuranoside 
hydrochloride was added to the cells.
Neurons were transfected on DIV 7 or 8 with plasmids contain-
ing cDNA for wild type and mutant GluN2A subunits, or the inert 
control β globin, using Lipofectamine 2000 (hereafter referred to 
as lipofectamine) in serum free non-trophic transfection medium 
composed of: 10% minimum essential media (MEM; +Earles, 
-L-glutamine), 88% Salt-Glucose-Glycine (comprising in mM 
114 NaCl, 26 NaHCO3, 5.3 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 
1 glycine, 30 D-glucose, 0.5 sodium pyruvate, with phenol red 
0.001%; (Bading et al., 1993)) supplemented with 1% antibiotic/
antimycotic and 1% insulin–transferrin–selenium supplement. For 
each cover slip, 2.3 μl of lipofectamine was mixed with 575 ng 
plasmid DNA comprising a 2:1 mass ratio of GluN2A/GluN2B 
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and eGFP cDNA. Cotransfection rate was 100% [cells were 
co-transfected using the above technique with cDNA encoding 
two fluorescent proteins (eGFP and mCherry) and observed for 
overlapping fluorescence 48 hours post transfection: 47/47 cells 
observed over 3 cover slips showed co-transfection]. Electrophysi-
ological recordings were made 48 hours post transfection.
Whole-cell recordings in cultured neurons
Recordings from cultured neurons were made at room temperature 
with neurons superfused (at a flow rate of 2 mL/min) with external 
recording solution composed of (in mM) 150 NaCl, 2.8 KCl, 10 
HEPES, 2 CaCl2, 10 glucose, 0.1 glycine, 0.003 tetrodotoxin; 
pH 7.35 using NaOH (300–330 mOsm). Transfected  cells were 
identified by eGFP expression (excitation at 470 nm, coolLED 
pE-100 (coolLED Ltd, Andover, UK)). In total, 150 μM NMDA 
was applied briefly twice to elicit desensitization, then reapplied 
until a steady state response was achieved (around 10 seconds 
of application) at which point 1 mM MgCl2 was co-applied 
until a new steady state was achieved. Experiments were then 
repeated after perfusion with 3 μM ifenprodil for one minute. 
Application of solutions was controlled manually. Patch-pipettes 
were made from thick-walled borosilicate glass (GC150F-7.5; 
Harvard Apparatus) using a P-87 puller (Sutter Instruments) to 
give a resistance of 2–4 MΩ when filled with internal solution 
containing (in mM): 141 K-gluconate, 2.5 NaCl, 10 HEPES, 11 
EGTA; pH 7.3 with KOH (300 mOsm). Currents were recorded 
using an Axopatch 200B amplifier (Molecular Devices). Data 
were filtered at 2 kHz and digitized at 20 kHz via a National 
Instruments BNC-2090A analogue-digital interface (National 
Instruments) using WinEDR software (v 3.2.7). Neurons were 
voltage-clamped at –65 mV, and recordings were rejected if 
the holding current was greater than 150 pA or if the series 
resistance was greater than 30 MΩ, or increased by greater than 
20% during the course of the recording. Capacitance was calculated 
by calculating the area under the current response to a 5 mV test 
pulse plotted against time (giving the charge) and dividing 
by the voltage of the test pulse. Capacitance provides an estimate 
of cell surface area. Current density was then calculated as 
current/capacitance.
Data analysis
Bar graphs depict individual cells (circles), means (columns) and 
standard error of the mean (SEM; error bars). R (v 3.1.2; R Core 
Team, 2014) was used to perform statistical tests. Comparisons 
between multiple means were performed by ANOVA. Comparisons 
between two means were performed by independent, two-tailed, 
Welch t–tests (which do not assume equal variance between 
groups), unless otherwise stated. The significance level used was 
p <0.05, corrected for multiple comparisons using the Bonferroni 
method. In figures, * indicates corrected significance levels of 
p <0.05, ** indicates p <0.01 and *** indicates p <0.001.
Materials
NMDA, NMDAR antagonists, ifenprodil and tetrodotoxin were 
purchased from Tocris Bioscience (Bristol, UK). Media, media 
supplements, Lipofectamine 2000, antibiotic/antimycotic and 
Β-27 were purchased from Invitrogen (Carlsbad, CA, USA). The 
remaining substances were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) unless stated otherwise in the text.
Results
The GluN2AR586K mutation has no effect on Mg2+ block or 
current density
We first expressed GluN2AWT and GluN2AR586K–containing 
NMDARs in X. laevis oocytes and made two-electrode voltage 
clamp recordings of block by Mg2+ of glutamate-evoked 
currents. We found no effect of GluN2AR586K on block by Mg2+ 
(Figure 1A–C).
To assess for any neuron-specific consequences of the variant, 
we then used transient transfection to over-express GluN2AR586K 
in cultured primary mouse cortical neurons. The interpretation of 
results in neurons is complicated by each cell giving a NMDA-
evoked response that arises in part from endogenous NMDAR 
subunits and in part from transfected subunits. The age of cul-
ture used (DIV 9) was chosen so that virtually all the endogenous 
GluN2 subunits were GluN2B (McKay et al., 2012). The GluN2B 
selective negative allosteric modulator ifenprodil could therefore 
be used to suppress the contribution of endogenous NMDARs 
and to confirm the transfection of the subunit of interest (GluN2B 
diheteromers show 80% block, but GluN2A diheteromers minimal 
block at the concentration of ifenprodil used (3 μM) (Williams, 
1993)).
GluN2AR586K expression was confirmed by reduced ifenprodil 
sensitivity compared to control transfections (Figure 2A–C; 
Table 1). As with oocytes, no effect was found on Mg2+ block 
in neurons (Figure 2A,B,D; Table 1). Current density was also 
unaffected by the GluN2AR586K mutation (Figure 2A,B,E; Table 1).
The GluN2AR586K mutation has no effect on single-channel 
properties
Finally, we used outside-out patches pulled from oocytes to 
assess the impact of GluN2AR586K on NMDAR single-channel 
conductance and mean open time. We found GluN2AR586K to have 
no effect (Figure 3A–D).
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Discussion
In the present study, we investigated the functional consequences 
of a GluN2A point variation found previously in a person with 
epilepsy/EEG abnormalities and intellectual disability. Using 
heterologous systems, we showed that the GluN2AR586K variant had 
no effect on any of the properties assessed: Mg2+ block, current 
density, conductance or mean open time.
The lack of functional consequences on permeation and Mg2+ block 
seen with the GluN2AR586K variant is in contrast to existing findings 
for several disease-associated NMDAR mutations, which have been 
found to have a substantial impact on NMDAR properties, including 
Mg2+ block (Burnashev & Szepetowski, 2015). This is not unsur-
prising given the diversity of mutations found in NMDAR subunits, 
with some resulting in complete loss of function of the allele, some 
impacting residues of established functional importance, and some 
causing conservative changes in residues of unknown function, 
such as studied here.
It was difficult to hypothesise what the likely impact of the 
GluN2AR586K variant might be, as little is known about the function 
of the M1-M2 linker region in which it is found. It is possible that 
the variant affects other properties that have not been investigated 
in this study. For example, conceivably it could influence traffick-
ing or zinc affinity, which is known to be regulated by C-terminal 
phosphorylation (Zheng et al., 1998). Further, the impact of the 
sequence change could manifest through indirect mechanisms, 
such as an impact on mRNA transcript stability, or epigenetic modi-
fications. Finally, a given variant may only have a physiological 
effect when partnered with a further variant (compound heterozy-
gosity). In general, it is impossible to exclude that a variant has 
some functional effect.
However, it is certainly possible that the variant does not alter 
NMDAR function, and that its presence in an individual with 
neurodevelopmental disorder was coincidental. This is particu-
larly likely as the variant was inherited, and because it has also 
subsequently been found in two out of 60,706 individuals with-
out severe paediatric disease collated by the Exome Aggregation 
Consortium (Lek et al., 2016) - although the existence of less severe 
neurodevelopmental disorders, such as adult onset epilepsy, in these 
individuals has not been excluded.
In conclusion, our limited functional studies suggest that the 
GluN2AR586K variant is probably benign.
Data availability
Data are deposited in project GluN2A R586K, Open 
Science Framework: DOI, 10.17605/OSF.IO/AWCNQ (Marwick, 
2017).
Figure 1. NMDARs containing GluN2AR586K show normal block by Mg2+ when expressed in oocytes. (A and B) Representative two-
electrode voltage-clamp recordings from oocytes expressing GluN2AWT or GluN2AR586K-containing NMDARs, showing current evoked by 
glutamate (30 μM) and inhibition by an approximately physiological concentration of Mg2+ (1 mM), in the continuous presence of glycine 
(30 μM). Holding potential –60 mV. Responses are normalised to the peak amplitude. (C) Summary data showing percentage block by Mg2+ 
at –60 mV. A t-test showed no significant difference between Mg2+ block in oocytes expressing GluN2AWT (n = 3, 92 ± 3 %) and GluN2AR586K 
(n = 5, 90 ± 2 %, t(2.9) = 0.46, p = 0.68).
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Figure 2. NMDARs containing GluN2AR586K show normal block by Mg2+ and normal current density when expressed in neurons. 
(A and B) Representative whole-cell voltage-clamp recordings from day in vitro (DIV) 9 neurons transfected with an inert control, GluN2AWT 
or GluN2AR586K, showing inhibition of current evoked by saturating NMDA (150 μM) by Mg2+ (1 mM) before and after one minute of ifenprodil 
(3 μM) application. Holding potential –65 mV. Responses are normalised to the peak amplitude. (C) Summary data showing percentage 
inhibition by ifenprodil, recorded from neurons as shown in A and B. A one-way ANOVA showed a significant effect of transfected subunit 
(F(2, 30) = 91, p = 1.8e-13), with post hoc t-tests (pcorr = 0.15) showing that neurons transfected with GluN2A
WT showed lower ifenprodil 
sensitivity than control transfection cells (t(15.7) = 12.6, p = 1.3e-9), as did neurons transfected with GluN2AR586K (t(18.3) = 13.8, p = 3.9e-11), 
and with no difference between GluN2AWT and GluN2AR586K (t(20.3) = 0.2, p = 0.88). These results confirm that the GluN2AR586K subunits 
were successfully trafficked to the membrane in neurons. (D) Summary data showing percentage inhibition by Mg2+ in the presence and 
absence of ifenprodil, recorded from neurons as shown in A and B. A two-way ANOVA showed a significant effect of transfected subunit 
(F(2, 30) = 7.5, p = 0.0022) on Mg2+ block and of the presence/absence of ifenprodil (F(1, 30) = 17.1, p = 0.0003), with a significant interaction 
(F(2, 30) = 4.4, p = 0.021). However, post hoc t-tests (pcorr = 0.15) showed no difference in Mg
2+ block in the absence of ifenprodil in neurons 
transfected with GluN2AR586K compared to GluN2AWT (t(20.3) = 0.86, p = 0.40), and no difference between GluN2AWT and neurons transfected 
with an inert control (t(13.8) = 2.2, p = 0.049). There was also no reduction in Mg2+ block associated with GluN2AR586K vs GluN2AWT in the 
presence of ifenprodil, when a greater proportion of response was attributable to the transfected subunits of interest (t(20.2) = 0.87, p = 0.40). 
(E) Summary data showing current density evoked by NMDA in the presence and absence of ifenprodil, recorded from neurons as shown 
in A and B. A two-way ANOVA showed a significant effect of transfected subunit (F(2, 30) = 7.5, p = 0.0023) and of the presence/absence 
of ifenprodil (F(1, 30) = 139, p = 9e-13), with a significant interaction (F(2, 30) = 16.8, p = 1.3e-5). However, post hoc t-tests (pcorr = 0.15) 
showed no difference in current density in the absence of ifenprodil in neurons transfected with GluN2AR586K compared to GluN2AWT (t(20.9) = 
0.5, p = 0.61), and no difference between GluN2AWT and neurons transfected with an inert control (t(18.8) = 1.2, p = 0.24). There was also no 
reduction in current density associated with GluN2AR586K vs GluN2AWT in the presence of ifenprodil (t(21) = 0.44, p = 0.66). Data are means ± 
SEM. Circles represent individual cells. See Table 1 for means and sample sizes.
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Table 1. Mg2+ block, current density and ifenprodil sensitivity in neurons transfected with an inert 












Globin 77 ± 2 97 ± 1 101 ± 1 48 ± 6 11 ± 1 10
GluN2AWT 24 ± 4 94 ± 1 94 ± 1 57 ± 5 44 ± 5 11
GluN2AR586K 25 ± 3 92 ± 2 93 ± 1 62 ± 6 47 ± 5 12
n refers to number of neurons. Data are means ± SEM. Statistical comparisons are reported in the Figure 2 legend. Mg2+ 
concentration used was 1 mM; ifenprodil 3 μM.
Figure 3. NMDARs containing GluN2AR586K show normal single-channel conductance. (A and B) Representative voltage-clamp 
recordings made from outside-out patches from oocytes transfected with GluN2AWT or GluN2AR586K-containing NMDARs in the presence of 
glutamate (30 μM) and glycine (30 μM). “C” = closed, “O” = open. (C) Summary data showing conductance, calculated as current amplitude/
holding potential. A t-test showed no significant difference in conductance in oocytes expressing GluN2AWT (n = 4, 58 ± 3 pS, total events = 
2555) and GluN2AR586K (n = 3, 61 ± 2 pS, total events = 1139, t(5.0) = 0.84, p = 0.44). (D) Summary data showing tau for mean open time, 
calculated by fitting exponential curves to open time frequency distributions. A single exponential was fitted in each case. A t-test showed 
no significant difference in mean open time in oocytes expressing GluN2AWT (n = 4, 4.0 ± 0.3 ms) and GluN2AR586K (n = 3, 3.5 ± 0.2 ms, 
t(5.0) = 1.32, p = 0.24). Data are means ± SEM. Circles represent individual cells.
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